Patents by Inventor Raymond T. Chung
Raymond T. Chung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170183411Abstract: The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular, methods of using agonists and antagonists of TGF-? superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders.Type: ApplicationFiled: December 12, 2016Publication date: June 29, 2017Inventors: Herbert Y. Lin, Jodie Babitt, Raymond T. Chung, Tarek A. Samad, Alan L. Schneyer, Clifford J. Woolf
-
Patent number: 9556251Abstract: The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular, methods of using agonists and antagonists of TGF-? superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders.Type: GrantFiled: July 16, 2014Date of Patent: January 31, 2017Assignee: THE GENERAL HOSPITAL CORPORATIONInventors: Herbert Y. Lin, Jodie Babitt, Raymond T. Chung, Tarek A. Samad, Alan L. Schneyer, Clifford J. Woolf
-
Publication number: 20160228575Abstract: The invention relates to methods of treatment of hepatitis C, dyslipidemia, insulin resistance, and inflammation, with flavonoid-sugar complexes.Type: ApplicationFiled: March 10, 2016Publication date: August 11, 2016Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Yaakov NAHMIAS, Martin L. YARMUSH, Raymond T. Chung
-
Publication number: 20150072927Abstract: The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular, methods of using agonists and antagonists of TGF-? superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders.Type: ApplicationFiled: July 16, 2014Publication date: March 12, 2015Inventors: Herbert Y. Lin, Jodie Babitt, Raymond T. Chung, Tarek A. Samad, Alan L. Schneyer, Clifford J. Woolf
-
Patent number: 8865168Abstract: The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular, methods of using agonists and antagonists of TGF-? superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders.Type: GrantFiled: October 18, 2012Date of Patent: October 21, 2014Assignee: The General Hospital CorporationInventors: Herbert Y. Lin, Jodie Babitt, Raymond T. Chung, Tarek A. Samad, Alan L. Schneyer, Clifford J. Woolf
-
Patent number: 8637023Abstract: The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular, methods of using agonists and antagonists of TGF-? superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders.Type: GrantFiled: February 28, 2012Date of Patent: January 28, 2014Assignee: The General Hospital CorporationInventors: Herbert Y. Lin, Jodie Babitt, Raymond T. Chung, Tarek A. Samad, Alan L. Schneyer, Clifford J. Woolf
-
USE OF MODULATORS OF COMPOUNDS OF TGF-BETA SUPERFAMILY TO REGULATE HEPCIDIN-MEDIATED IRON METABOLISM
Publication number: 20130149304Abstract: The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular, methods of using agonists and antagonists of TGF-? superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders.Type: ApplicationFiled: October 18, 2012Publication date: June 13, 2013Inventors: Herbert Y. Lin, Jodie Babitt, Raymond T. Chung, Tarek A. Samad, Alan L. Schneyer, Clifford J. Woolf -
Patent number: 8293236Abstract: The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular methods of using agonists and antagonists of TGF-? superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders.Type: GrantFiled: June 28, 2011Date of Patent: October 23, 2012Assignee: The General Hospital CorporationInventors: Herbert Y. Lin, Jodie Babitt, Raymond T. Chung, Tarek A. Samad, Alan L. Schneyer, Clifford J. Woolf
-
Publication number: 20120258105Abstract: The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular, methods of using agonists and antagonists of TGF-? superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders.Type: ApplicationFiled: February 28, 2012Publication date: October 11, 2012Inventors: Herbert Y. Lin, Jodie Babitt, Raymond T. Chung, Tarek A. Samad, Alan L. Schneyer, Clifford J. Woolf
-
Publication number: 20120094939Abstract: The present invention is directed to compounds of formulae (I) and (II) and pharmaceutically acceptable forms thereof; pharmaceutical compositions thereof; and methods of treating a viral infection, such as a hepatitis C virus (HCV) infection, by administering to a subject diagnosed with or being susceptible to the viral infection a compound of formulae (I) and (II), a pharmaceutically acceptable form thereof, or a pharmaceutical composition thereof. The present invention is also directed to high-throughput methods of identifying compounds able to modulate hepatitis C virus (HCV) replication activity.Type: ApplicationFiled: April 4, 2008Publication date: April 19, 2012Inventors: Stuart L. Schreiber, Raymond T. Chung, Lee F. Peng, Sun Suk Kim, Sirinya Matchacheep, John A. Porco, JR., Aaron B. Beeler
-
Publication number: 20120064076Abstract: The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular methods of using agonists and antagonists of TGF-? superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders.Type: ApplicationFiled: June 28, 2011Publication date: March 15, 2012Inventors: Herbert Y. Lin, Jodie Babitt, Raymond T. Chung, Tarek A. Samad, Alan L. Schneyer, Clifford J. Woolf
-
Publication number: 20120009601Abstract: The present invention is directed, in part, to methods and compositions comprising inhibitors of micro RNA-145 and activators of the TGF-? signaling pathway to permit reprogramming using only small molecule compounds. Also described herein are methods to distinguish cancer cells or cells having cancerous potential in human iPS cell populations, based on determining the balance of p21-p53 expression levels, or ratio thereof in reprogrammed cells. In further aspects, methods and compositions to cause redifferentiation of a hepatoma cell to a hepatocye-like cell using acyclic retinoid and inhibitors of AKR1B10 are provided.Type: ApplicationFiled: July 7, 2011Publication date: January 12, 2012Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Hisashi Moriguchi, Raymond T. Chung
-
Publication number: 20110312985Abstract: The invention relates to methods of treatment of hepatitis C, dyslipidemia, insulin resistance, and inflammation, with flavonoid-sugar complexes.Type: ApplicationFiled: October 7, 2009Publication date: December 22, 2011Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Yaakov Nahmias, Martin L. Yarmush, Raymond T. Chung
-
Patent number: 7968091Abstract: The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular, methods of using agonists and antagonists of TGF-? superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders.Type: GrantFiled: February 16, 2006Date of Patent: June 28, 2011Assignee: The General Hospital CorporationInventors: Clifford J. Woolf, Tarek A. Samad, Herbert Y. Lin, Jodie Babitt, Raymond T. Chung, Alan L. Schneyer
-
Publication number: 20080260736Abstract: The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular, methods of using agonists and antagonists of TGF-? superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders.Type: ApplicationFiled: February 16, 2006Publication date: October 23, 2008Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Herbert Y. Lin, Jodie Babitt, Raymond T. Chung, Tarek A. Samad, Alan L. Schneyer, Clifford J. Woolf